Alteration of Interferon-α/β Receptors in Chronic Hepatitis B Patients

Fanli Meng,Jiefei Wang,Jian Ge,Xiaopeng Fan,Bing Wang,Liyan Han,Tatiana Kisseleva,YongHan Paik,David A. Brenner,Kai Wang
DOI: https://doi.org/10.1007/s10875-011-9518-6
IF: 8.542
2011-01-01
Journal of Clinical Immunology
Abstract:Background The present study determined type I interferon (IFN) receptor (interferon-α/β receptor (IFNAR)) and its predicable role in interferon-α2b treatment in chronic hepatitis B (CHB) patients. Methods Expression of IFN-α/βR-1 and IFN-α/βR-2 in peripheral blood mononuclear cells and in liver tissue was measured by flow cytometry, immunofluorescence, immunohistochemistry and RT-PCR. Results IFN-α/βR-1 and IFN-α/βR-2 in monocytes and lymphocytes increased in CHB patients. Expression of IFNAR-1 and IFNAR-2 in liver had positive correlation with HBV-DNA in liver tissue. Expression of IFN-α/βR in lymphocytes and monocytes increased in the first month, but then decreased during the subsequent interferon-α2b treatment, patients who had higher levels of IFN-α/βR-2 in monocytes prior to therapy showed better viral response than those with lower levels. Conclusions Expression of IFN-α/βR-2 in monocytes can be used as a predictable parameter to evaluate the effect of IFN-α treatment in CHB patients.
What problem does this paper attempt to address?